Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-MAD in Newly-diagnosed Extranodal NK/T-cell Lymphoma
NCT03246750Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Extranodal NK/T-cell lymphoma (ENKTL). Started Jan 2019; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03246750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246750.